

L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]

Luca Potestio , Fabrizio Martora , Sara Cacciapuoti, Matteo Megna, Alessia Villani, Angelo Ruggiero 

Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

Correspondence: Angelo Ruggiero, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 - 081 - 7462457, Fax +39 - 081 - 7462442, Email angeloruggiero1993@libero.it

Dear editor

We have read with great interest the letter by dos Santos et al entitled “L-lysine as an Alternative Treatment for Pityriasis Rosea (PR)”,¹ commenting our previously published manuscript reviewing current literature on the PR and PR-like eruption following COVID-19 vaccination.² It is well known that there is an association between PR and human herpesvirus (HHV) 6–7, which, like all HHV, is characterized by the ability to establish lifelong latency.³ Among the several cutaneous reactions and viral reactivations reported following COVID-19 vaccination, PR was one of the commonest.^{4,5} Among the proposed pathogenetic mechanisms, despite the exact correlation is not still understood, it has been hypothesized that the exposure to the viral antigen boosts the cell-mediated immune response, and this immune response can sometimes become dysregulated, leading to inflammation and reactivation of latent viral infections, including human herpesviruses HHV6 and HHV7, linked to PR.⁶ Moreover, therapeutic approaches to PR have not been discussed in our review, since this disease is usually self-limited.²

In this context, dos Santos et al showed that one case of PR following the second dose of AZD1222 was treated with the L-lysine + L-arginine protocol, based on the capacity of lysine to inhibit the availability of arginine through competitive antagonism, leading to viral replication impairment.⁷

According to authors, this therapeutic approach should be suggested in severe cases of PR, regardless the COVID-19 vaccination.

Despite the watchful waiting strategy, coupled with the treatment of eventually associated symptoms such as pruritus with oral antihistamines, it is the mainstay of treatment of PR; patients with severe disease or requiring faster resolution may benefit from other therapies such as antivirals (acyclovir) and phototherapy.^{8–10} In this context, L-lysine + L-arginine protocol may be an interesting option, also as monotherapy. Certainly, further studies are required to establish the best treatment algorithm for PR.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Dos Santos VAB, Pedrazini MC. L-lysine as an alternative treatment for pityriasis rosea (PR) [Letter]. *Clin Cosmet Invest Dermatol*. 2024;17:433–434. doi:10.2147/CCID.S461722
2. Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A. Pityriasis rosea and pityriasis rosea-like eruption following COVID-19 vaccination: a narrative review. *Clin Cosmet Invest Dermatol*. 2024;17:51–57. doi:10.2147/CCID.S447834
3. Pantry S, Medveczky P. Latency, integration, and reactivation of human herpesvirus-6. *Viruses*. 2017;9(7):194. doi:10.3390/v9070194
4. Ruggiero A, Megna M, Fabbrocini G, Martora F. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. *Clin Exp Dermatol*. 2022;47(10):1863–1864. doi:10.1111/ced.15286
5. Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. *J Cosmet Dermatol*. 2023;22(1):32–33. doi:10.1111/jocd.15414

6. Khan I, Elsanousi AA, Shareef AM, Tebha SS, Arif A, Gul S. Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after Covid-19 vaccine: a systematic review. *Immun Inflamm Dis*. 2023;11(4):e804. doi:10.1002/iid3.804
7. Pedrazini MC, Silva MH. Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-ASTRAZENECA vaccine: case report and brief literature review. *Dermatologic Therapy*. 2021;34(6). doi:10.1111/dth.15129
8. Rodriguez-Zuniga M, Torres N, Garcia-Perdomo H. Effectiveness of Acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis. *An Bras Dermatol*. 2018;93(5):686–695. doi:10.1590/abd1806-4841.20187252
9. Villalon-Gomez JM. Pityriasis rosea: diagnosis and treatment. *Am Fam Physician*. 2018;97(1):38–44.
10. Marasca C, Ruggiero A, Napolitano M, Fabbrocini G, Megna M. May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? *Med Hypotheses*. 2020;143:109853. doi:10.1016/j.mehy.2020.109853

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical, Cosmetic and Investigational Dermatology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical, Cosmetic and Investigational Dermatology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical, Cosmetic and Investigational Dermatology

Dovepress

Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>

<https://doi.org/10.2147/CCID.S464230>